Peer-reviewed veterinary case report
Pullulan-conjugated Der f 2 immunotherapy for dog atopic dermatitis
By Kawano, Kouji & Mizuno, Takuya·Published in Veterinary dermatology·2017·Primo Animal Hospital Tokyo Animal Allergy Medical Center (AAMC), Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A pilot study of the effect of pullulan-conjugated Der f 2 allergen-specific immunotherapy on canine atopic dermatitis.
- Species:
- dog
Plain-English summary
A group of 13 dogs with atopic dermatitis (a skin condition causing itching and inflammation) were treated with a new immunotherapy using a dust mite protein called Der f 2. After 60 days of treatment, the dogs showed significant improvement in their skin condition and itching levels, with scores dropping from high levels to much lower ones. Additionally, the amount of oral steroids needed to manage their symptoms decreased after starting the therapy. This suggests that the Der f 2 immunotherapy could be an effective option for dogs suffering from this type of allergy.
People also search for: dog itching treatment · atopic dermatitis in dogs · Der f 2 immunotherapy for dogs
Abstract
BACKGROUND: Dermatophagoides farinae is a major and common environmental house dust mite involved in canine atopic dermatitis (CAD). A formulation of recombinant protein Der f 2 is available in Japan for immunotherapy in dogs. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy of a recombinant allergen based on Der f 2-pullulan for the treatment of cAD. METHODS: Dogs (n = 15) with atopic dermatitis were administered Der f 2 conjugated with pullulan (-P). Two dogs were eliminated because of death unrelated to the treatment during the study. The remaining 13 cases were included in the analysis. Clinical signs were evaluated with the Canine Atopic Dermatitis Lesion Index (CADLI) and pruritus levels were evaluated from 0 to 10 with a pruritus Visual Analog Scale (PVAS). RESULTS: The mean ± standard deviation (SD) of CADLI [before allergen-specific immunotherapy (pre-ASIT) 21.9 ± 9.7; 60 days post-ASIT 9.8 ± 8.4 and 120 days post-ASIT 9.7 ± 8.2] and the mean ± SD of PVAS [pre-ASIT 7.2 ± 1.2; post-ASIT (60 days) 2.6 ± 2.2 and post-ASIT (120 days) 3.1 ± 2.5] significantly decreased after treatment (Dunnett's test, P < 0.05). Furthermore, the total doses of oral glucocorticoids in the two months pre-ASIT significantly decreased in comparison with two months post-ASIT (123 ± 72.6 mg vs. 70.0 ± 84.3 mg; Dunnett's test, P < 0.05). CONCLUSIONS AND CLINICAL IMPORTANCE: The results indicate the effectiveness of Der f 2-P recombinant protein in the treatment of dogs with CAD and testing positive to D. farinae.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28776792/